CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Three Problems Faced By Biotech Companies

Three Problems Faced By Biotech...

Exocel Bio Ushers In The Next Generation Of Regenerative Aesthetics With All-Natural Exosomes Serum, Exovextm

Exocel Bio Ushers In The Next...

Achieving trial master file quality, timeliness and completeness

Achieving trial master file quality,...

Antibodies: The Building Blocks of Cures

Antibodies: The Building Blocks of Cures

The Dynamic Commercial Aspects of Life Sciences

The Dynamic Commercial Aspects of...

The Future of Life Sciences Industry

The Future of Life Sciences Industry

Accelerating Digital Transformation through an Agile, Customer-centric Approach

Accelerating Digital Transformation...

Re-imagining Learning in a Post-Pandemic World

Re-imagining Learning in a...

Three Problems Faced By Biotech Companies

Three Problems Faced By Biotech...

Exocel Bio Ushers In The Next Generation Of Regenerative Aesthetics With All-Natural Exosomes Serum, Exovextm

Exocel Bio Ushers In The Next...

Achieving trial master file quality, timeliness and completeness

Achieving trial master file quality,...

Antibodies: The Building Blocks of Cures

Antibodies: The Building Blocks of Cures

The Dynamic Commercial Aspects of Life Sciences

The Dynamic Commercial Aspects of...

The Future of Life Sciences Industry

The Future of Life Sciences Industry

Accelerating Digital Transformation through an Agile, Customer-centric Approach

Accelerating Digital Transformation...

Re-imagining Learning in a Post-Pandemic World

Re-imagining Learning in a...

Ginkgo Enters Into A Definitive Agreement To Acquire Zymergen

Life Sciences Review Life Sciences Review | Tuesday, August 02, 2022
Tweet

The Acquisition by Ginkgo is expected to enhance its platform significantly by integrating robust automation and software capabilities and diverse biological engineering expertise.


FREMONT, CA: "We have always had incredible respect for the Zymergen team and the strength of the technologies that they have built for cell programming. We are thrilled to integrate Zymergen's capabilities into our Foundry, which we expect to accelerate the growth of our platform as we continue to deliver on our mission to make biology easier to engineer for our customers, helping us drive down the costs of cell programming as we invest in scale. We can't wait to welcome Zymergen's technical teams, who will support our scaling objectives." says Jason Kelly, CEO, and co-founder of Ginkgo Bioworks.


Ginkgo Bioworks, one of the premier horizontal platforms for cell programming, and Zymergen revealed a definitive agreement under which Ginkgo would acquire Zymergen in an all-stock transaction valued at approximately $300 million in market capitalization. The agreement's terms are unanimously approved by both the companies' boards of directors. 


 


Ginkgo is a horizontal platform that serves customers across industries rather than producing its products. It will help Zymergen evaluate strategic alternatives for their Advanced Materials and Drug Discovery businesses, which have valuable product pipelines and rapid prototyping capabilities. Zymergen will continue its solo cost-cutting activities, such as workforce reductions and program optimization. Finally, acquiring Zymergen personnel is expected to assist Ginkgo in planning to recruit as the platform scales. Once the integration is complete, Ginkgo expects these efforts to reduce incremental run-rate operating expenses associated with the combination.


This acquisition brings together two highly complementary firms that believe biology has the potential to alter several industries, including manufacturing, agriculture, and medicine. Ginkgo intends to incorporate into its Foundry Zymergen's key automation and software technologies for scaling strain engineering capacity, including Zymergen's machine learning and data science tools for exploring known and unexplored genetic design space. Following the deal, Ginkgo clients will benefit from developing Ginkgo's library of biological assets ("Codebase").


Weekly Brief

loading
Top 10 Biotech Companies in Latin America - 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/ginkgo-enters-into-a-definitive-agreement-to-acquire-zymergen--nwid-929.html